Tigecycline- A New Tetracycline Derivative for MRSA Infection

Abstract

Introduction: The inevitable consequence of the widespread use of antimicrobial agents has been the emergence of antibioticresistant pathogens, fueling an ever-increasing need for new antimicrobial agents.
Methodology: The clinical use and therapeutic effects of the new drug Tigecycline is described.
Result: Tigecycline is an example of a new drug developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was approved by FDA in 2005